On April 17, the fateful Juno Therapeutics company announced the appointment of Genentech's former scientist Sunil Agarwal as president of research and development, leading a new research and development organization to help accelerate the progress of its CAR-T therapy, Juno After a CAR-T "rocket" crashed, Juno was ready to go back to the CAR-T therapy market.
On April 17, 2017, the troubled Juno Therapeutics company announced the appointment of Genentech's former scientist Sunil Agarwal as president of research and development to lead a new research and development organization to help accelerate the progress of its CAR-T therapy. After Juno's first CAR-T "rocket" crashed, Juno was ready to go back to the CAR-T therapy market.
Juno's R&D department is changing blood, so why is Dr. Sunil Agarwal also?
Sunil Agarwal
Being able to join Juno as president of research and development, known as the essentials for Juno's CAR-T therapy to return to market leadership, Sunil Agarwal is also a great god.
Dr. Sunil Agarwal holds a bachelor's degree in neurobiology from Cornell University and a medical degree from Tufts University School of Medicine. He completed his residency at the Children's National Medical Center in Washington, DC, and then joined the George Washington University School of Medicine as a professor.
Dr. Agarwal has held several senior leadership positions at Genentech, most recently as Senior Vice President of Global Development for Ophthalmology, Metabolism, Neuroscience, Immunology and Infectious Diseases. He is responsible for everything from proof of concept (PoC) to the fourth phase of the global development plan. He is also a member of the Gene Technology Research and Early Development (gRED) and Pharmaceutical Research and Early Development Committee (pRED) committees, which define strategies for investigating all molecules of new drugs through PoC in many therapeutic areas, including oncology. He has led global certification of multiple treatments and has successfully built and led large global development organizations across multiple regions.
Prior to joining Juno, Dr. Agarwal's last industry role was Chief Medical Officer, Executive Vice President of Ultragenyx.
Hans Bishop, CEO of Juno Therapeutics
Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.zhongzhinanlighting.com